180 Life Sciences Corp.

180 Life Sciences has completed a $425 million private placement to fund a new Ethereum treasury strategy. The company plans to invest the majority of the funds in purchasing Ethereum, while continuing its existing iGaming business and monetizing its biotechnology patents. As part of the strategic shift, new board members have been appointed and an external management team has been engaged to implement a yield-focused crypto program. » More on de.investing.com

180 Life Sciences has completed a PIPE transaction worth approximately $425 million to implement a treasury strategy focused on Ethereum (ETH). The company plans to rebrand as ETHZilla Corporation and intends to use the proceeds primarily to purchase ETH and for general corporate purposes. Additionally, new patents have been secured, the annual general meeting for 2025 has been announced, and measures for executive stock compensation have been approved. » More on de.investing.com

Shareholders of 180 Life Sciences have approved a drastic increase in authorized common shares from 100 million to 1 billion at the annual general meeting. Additionally, new incentive plans, accelerated stock compensation for executives, and a share buyback to streamline the capital structure were adopted. The company also secured two new patents in the field of postoperative cognitive dysfunction. » More on de.investing.com